"Hair loss magic medicine" is expected to be launched!

In this world, there are always people quietly watching you and your ha.

In this world, there are always people quietly watching you and your ha.

Recently, Eli Lilly and Incyte jointly announced that the co-developed JAK inhibitor baricitinib has achieved excellent results in two phase III clinical studi.

If successfully approved, it will become the world's first JAK inhibitor for the treatment of severe alopecia area.

The world's first

It is reported that there are more than 250 million people with hair loss in my country, which is equivalent to 1 in 6 people losing hair! (includes normal hair loss and symptoms caused by physiological mechanisms)

At present, which other pharmaceutical companies are quietly watching your "hair"?

At present, which other pharmaceutical companies are quietly watching your "hair"?

Only 2 drugs have been approved in the world

Only 2 drugs have been approved in the world

According to the cause of hair loss, hair loss can be roughly divided into androgenetic alopecia, alopecia areata, and hair loss caused by anticancer drug treatme.

Androgenetic alopecia, alopecia areata, and hair loss caused by anticancer drug treatment,e.

In terms of drug treatment, currently only two drugs, Finasteride and Minoxidil, have been approved globally, but these two drugs are generally effective and have obvious side effec.

In terms of drug treatment, currently only two drugs, Finasteride and Minoxidil, have been approved globally, but these two drugs are generally effective and have obvious side effec.

There is currently no effective treatment for hair loss caused by anticancer drug treatme.

The following pharmaceutical companies are watching your "hai.

The following pharmaceutical companies are watching your "hai.

Table 1 does not fully count the pipelines currently under development in the clinical sta.

For androgenetic alopecia, the fastest progress is the Furitane of the pioneering pharmaceutical indust.

For androgenetic alopecia, the fastest progress is the Furitane of the pioneering pharmaceutical indust.

On December 31, 2021, the first patient enrollment and administration were completed in the China Phase III clinical trial of furatan in the treatment of male androgenetic alopec.

For alopecia areata, the fastest progress is Lilly's baricitin.

For alopecia areata, the fastest progress is Lilly's baricitin.

The results of two phase III clinical studies of baricitinib showed that approximately one-third of patients treated with baricitinib at a dose of 4 mg achieved scalp hair coverage of more than 80% with a favorable safety profi.

It is reported that oral baricitinib tablets are expected to be reviewed and listed in the United States, Europe and Japan, which will open the door to the treatment of alopecia area.

In addition, Pfizer's JAK3/TEC inhibitor PF-06651600, Concert Pharmaceuticals' JAK1/2 inhibitor CTP-543, Zejing Bio's Jaketinib and Restone Bio's SHR0302 have all received clinical trials Positive results, and in late-stage clinical development, show great potenti.

86 billion "Blue Ocean"

86 billion "Blue Ocean"

In fact, hair loss has become a global "disease of the ag.

According to the World Health Organization, about 6 billion of the world's 7 billion people suffer from hair lo.

According to a conservative estimate by Market Date Forecast, an authoritative data analysis agency, the global hair loss market will reach at least US$81 billion in 2021 and is expected to grow to US$144 billion (about 86 billion yuan) in 2026, with an average annual compound growth rate of

144 billion US dollars (about 86 billion yuan)

Figure 1 Forecast analysis of global hair loss market size

In China, according to data from the National Health and Medical Commission, there are more than 250 million people with hair loss in China, which is equivalent to 1 in 6 people losing ha.

In China, according to data from the National Health and Medical Commission, there are more than 250 million people with hair loss in China, which is equivalent to 1 in 6 people losing ha.

Among them, the proportion of people with hair loss before the age of 30 is as high as 6
It can be said that the post-90s have become the "main force" of hair lo.

The rejuvenation of the hairline has become a "top priority" for young peop.

Correspondingly, according to Frost & Sullivan's analysis, the scale of China's hair loss market in 2021 is about 24 billion yuan, and it is expected to reach 42 billion yuan in 2026, with an average annual compound growth rate of nearly 1

Figure 2 Forecast and analysis of China's hair loss market size

Alopecia areata mentioned above is the second most common hair loss symptom in the world, with about 147 million patients worldwide and about 4 million patients in Chi.

It is an autoimmune disease that causes partial or complete loss of hair on the scalp, face, or other parts of the body as the immune system attacks the hair follicl.

Alopecia areata symptoms often start in childhood and can occur in people of any age, gender and ra.

Alopecia areata symptoms often start in childhood and can occur in people of any age, gender and ra.

Unpredictable hair loss has brought a serious psychological burden to the society, and there is a huge market demand for hair loss preventi.

How to save the "bald star"?

How to save the "bald star"?

With economic development, the continuous improvement of living standards and the continuous increase of work pressure, as well as people paying more and more attention to their appearance, "baldness" has become a "top priority" for all age grou.

Drug treatment has become the most important choice for "bald stars", and anti-hair loss drugs have become one of the fastest growing markets at home and abro.

With the approval of baricitinib, the almost blank tens of billions of hair loss drug treatment market has just been open.

At present, the mechanism of action of hair loss is still a myste.

At present, the mechanism of action of hair loss is still a myste.

The tiny hair follicle organ follows an autonomous internal clock that drives hair follicles through cycles of growth, regression, and rest, but the mechanisms that regulate it are currently unkno.

If we can understand how hair follicles work, we can use pharmacological guidance to interfere with this inherent clock mechanism in human hair follicles, and the corresponding drugs will be very powerful drugs for the treatment of hair lo.

On the other hand, drug development can consider only local inhibition of the signaling pathway mediated by the target and its recepto.

On the other hand, drug development can consider only local inhibition of the signaling pathway mediated by the target and its recepto.

Focus on local mechanisms to avoid the reduction of systemic hormone levels and the resulting clinical side effects while blocking signal transduction to stimulate germinal grow.

Is "first-class business" likely to become the main battlefield for future consumption upgrades? How can the demand of the "head market" be fully tapped? Test the wisdom of major enterpris.

Is "first-class business" likely to become the main battlefield for future consumption upgrades? How can the demand of the "head market" be fully tapped? Test the wisdom of major enterpris.